Literature DB >> 17981206

Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.

Anna Richards1, David Kavanagh, John P Atkinson.   

Abstract

In this chapter, we examine the role of complement regulatory activity in atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). These diseases are representative of two distinct types of complement-mediated injury, one being acute and self-limited, the other reflecting accumulation of chronic damage. Neither condition was previously thought to have a pathologic relationship to the immune system. However, alterations in complement regulatory protein genes have now been identified as major predisposing factors for the development of both diseases. In aHUS, heterozygous mutations leading to haploinsufficiency and function-altering polymorphisms in complement regulators have been identified, while in AMD, polymorphic haplotypes in complement genes are associated with development of disease. The basic premise is that a loss of function in a plasma or membrane inhibitor of the alternative complement pathway allows for excessive activation of complement on the endothelium of the kidney in aHUS and on retinal debris in AMD. These associations have much to teach us about the host's innate immune response to acute injury and to chronic debris deposition. We all experience cellular injury and, if we live long enough, will deposit debris in blood vessel walls (atherosclerosis leading to heart attacks and strokes), the brain (amyloid proteins leading to Alzheimer's disease), and retina (lipofuscin pigments leading to AMD). These are three common causes of morbidity and mortality in the developed world. The clinical, genetic, and immunopathologic understandings derived from the two examples of aHUS and AMD may illustrate what to anticipate in related conditions. They highlight how a powerful recognition and effector system, the alternative complement pathway, reacts to altered self. A response to acute injury or chronic debris accumulation must be appropriately balanced. In either case, too much activation or too little regulation promotes undesirable tissue damage and human disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981206     DOI: 10.1016/S0065-2776(07)96004-6

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  32 in total

1.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

2.  Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.

Authors:  Budhaditya Mazumdar; Hangeun Kim; Keith Meyer; Sandip K Bose; Adrian M Di Bisceglie; Ratna B Ray; Michael S Diamond; John P Atkinson; Ranjit Ray
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.

Authors:  Dennis E Hourcade; Lynne M Mitchell
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

Review 4.  Autoimmunity: homeostasis of innate immunity gone awry.

Authors:  Hyon Ju Park; John P Atkinson
Journal:  J Clin Immunol       Date:  2012-10-11       Impact factor: 8.317

Review 5.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

6.  Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging.

Authors:  Elaine Agius; Katie E Lacy; Milica Vukmanovic-Stejic; Ann L Jagger; Anna-Pia Papageorgiou; Sue Hall; John R Reed; S John Curnow; Judilyn Fuentes-Duculan; Christopher D Buckley; Mike Salmon; Leonie S Taams; James Krueger; John Greenwood; Nigel Klein; Malcolm H A Rustin; Arne N Akbar
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

Review 7.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

Review 8.  Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.

Authors:  Christine A Curcio; Mark Johnson; Jiahn-Dar Huang; Martin Rudolf
Journal:  Prog Retin Eye Res       Date:  2009-08-19       Impact factor: 21.198

Review 9.  Inhibiting complement activation on cells at the step of C3 cleavage.

Authors:  M Kathryn Liszewski; Celia J Fang; John P Atkinson
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 10.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.